The United States Department of Justice has announced that it closes its investigation into PLATO clinical trial for AstraZeneca’s Brilinta.
In the PLATO study, Brilinta (ticagrelor) was compared to clopidrogel combined with acetylsalicylic acid. The studied showed that ticagrelor reduced cardiovascular events better than the rival. The Department of Justice started an investigation in October 2013 of the study but the government has now stated that it is not planning any further action of the investigation.
“We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit Brilinta offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we are committed to delivering the full potential of this important medicine,” commented Pascal Soriot, Chief Executive Officer.